Senior executives from multinational enterprises attending the China Development Forum (CDF) 2025 have said that China remains one of their top investment destinations.
The two-day forum, which opened on Sunday, brought together 86 official delegates from multinational companies across 21 countries - a record high, with American firms accounting for the largest share of the number, totaling 27 enterprises.
Some U.S. companies pointed out that the CDF has become the most significant platform for high-level communication and cooperation between the Chinese government and leaders from the international business and academic communities, as they are able to gain insights into the latest information on China's economic and social progress.
"The forum has been very informative. I think it's the interaction between the government officials, ministers and then the business community on how we can certainly benefit China and the development opportunities here, but how we can collectively benefit across the globe," said Michael Nelson, CEO of American direct selling giant Amway Global.
"I'm encouraged. There's a commitment to growth. There's a commitment to improving consumption. And there's a commitment to improving the living for Chinese citizens and that gets us excited because that lines up perfectly with what we do at Otis," said Judy Marks, CEO of world-leading elevator manufacturer Otis Worldwide Corporation.
The participating multinational companies represent a diverse array of industries, including finance and insurance, pharmaceuticals and health care, energy and mining, as well as foodstuff and consumer goods.
Many said that China plays a pivotal role in the world economy, and the high-quality development of the Chinese economy will continue to provide significant market opportunities for multinational enterprises.
"I think that China is working hard to grow the economy, and be clear about attracting global investment, that the economy is not becoming more closed, it's becoming more open. We have this kind of high ambition for the Chinese market," said David A. Ricks, CEO of the U.S.-based pharmaceutical company Eli Lilly.

China remains top investment destination: US multinationals